Multiple myeloma bone disease models with integrated bone marrow adipose tissue for advancing personalized medicine
4 affiliations
- 1Group for Hematology and Stem Cells, Institute for Medical Research, National Institute of Republic of Serbia, University of Belgrade
- 2Institute of Orthopedics Banjica
- 3Faculty of Medicine, University of Belgrade
- 4Mellanby Centre for Musculoskeletal Research and School of Medicine and Population Health, Faculty of Health, University of Sheffield
Abstract
Multiple myeloma (MM) is an incurable hematological cancer of monoclonal plasma cells, where patients commonly develop osteolytic bone disease. The pathogenesis of myeloma is known to be strongly dependent on the bone marrow (BM) microenvironment, but despite this, successful therapies targeting the niche constituents are lacking. Increased body weight and obesity are associated with poor prognosis and disease outcome, making adipose tissue an important regulatory factor in myeloma. Bone marrow adipose tissue (BMAT) has been recognized as a unique adipose depot, with strong implications in MM bone disease. In this review, we discuss the development of advanced adipose tissue models, including BMAT, and their utility for the design of precise and potentially personalized myeloma therapies. Compared to other adipose models, BMAT models require a complex composition to mimic the BM niche, including BM adipocytes, extracellular matrix, immune cells, bone cells, distinct stem/progenitor cell populations plus myeloma cells. In this sense, BMAT-permissive multicellular 3D models, such as bone and BM organoids, could have significant potential to recapitulate the MM niche. Although advanced 3D models based on induced pluripotent stem cells recreate the mesenchymal–vascular–hematopoietic tissues and BM microenvironment, adult BM recapitulation is still challenging. Incorporating patient-derived cells such as myeloma cells and BM adipocytes into these models will improve the accuracy of determining drug responses, disease progression, and patient-specific therapies, particularly in relapsed and/or refractory MM. Altogether, advanced patient-derived 3D model systems provide a more reliable experimental platform for mechanistic and translational studies across the whole BM and bone ecosystem.
Related
- Advancing T Cell Engagers in Multiple Myeloma: Structural Design and Clinical Optimization to Address Current Limitations.
- Integrated hs-cTnI, global longitudinal strain, and coronary artery calcium for risk stratification of anthracycline-related cardiac dysfunction in multiple myeloma
- CLINICAL CHARACTERIZATION OF AN EINSTEIN HOSPITAL BIOBANK DERIVED COHORT FOR INTEGRATED MULTI-OMICS ANALYSIS IN PATIENTS WITH MULTIPLE MYELOMA
- Evolution of Precision Oncology, Personalized Medicine, and Molecular Tumor Boards
- Theratyping for personalized medicine across cystic fibrosis disease models
BibTeX
@article{trivanovic2026multiple,
title = {{Multiple myeloma bone disease models with integrated bone marrow adipose tissue for advancing personalized medicine}},
author = {Drenka Trivanović and Slavko Mojsilović and Nikola Bogosavljević and Marko Vujačić and Alanna C. Green and Aleksandra Jauković},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1982576},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1982576/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Multiple myeloma bone disease models with integrated bone marrow adipose tissue for advancing personalized medicine
AU - Drenka Trivanović
AU - Slavko Mojsilović
AU - Nikola Bogosavljević
AU - Marko Vujačić
AU - Alanna C. Green
AU - Aleksandra Jauković
PY - 2026
DA - 2026/10/28
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1982576
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1982576/full
AB - Multiple myeloma (MM) is an incurable hematological cancer of monoclonal plasma cells, where patients commonly develop osteolytic bone disease. The pathogenesis of myeloma is known to be strongly dependent on the bone marrow (BM) microenvironment, but despite this, successful therapies targeting the niche constituents are lacking. Increased body weight and obesity are associated with poor prognosis and disease outcome, making adipose tissue an important regulatory factor in myeloma. Bone marrow adipose tissue (BMAT) has been recognized as a unique adipose depot, with strong implications in MM bone disease. In this review, we discuss the development of advanced adipose tissue models, including BMAT, and their utility for the design of precise and potentially personalized myeloma therapies. Compared to other adipose models, BMAT models require a complex composition to mimic the BM niche, including BM adipocytes, extracellular matrix, immune cells, bone cells, distinct stem/progenitor cell populations plus myeloma cells. In this sense, BMAT-permissive multicellular 3D models, such as bone and BM organoids, could have significant potential to recapitulate the MM niche. Although advanced 3D models based on induced pluripotent stem cells recreate the mesenchymal–vascular–hematopoietic tissues and BM microenvironment, adult BM recapitulation is still challenging. Incorporating patient-derived cells such as myeloma cells and BM adipocytes into these models will improve the accuracy of determining drug responses, disease progression, and patient-specific therapies, particularly in relapsed and/or refractory MM. Altogether, advanced patient-derived 3D model systems provide a more reliable experimental platform for mechanistic and translational studies across the whole BM and bone ecosystem.
SN - 2234-943X
ER -